Annual Drug Patent Expirations for QTERNMET+XR
Qternmet Xr is a drug marketed by Astrazeneca Ab and is included in one NDA. There are seven patents protecting this drug.
Drug patent litigation for QTERNMET XR.
This drug has three hundred and seventy patent family members in forty-seven countries.
The generic ingredient in QTERNMET XR is dapagliflozin; metformin hydrochloride; saxagliptin hydrochloride. Additional details are available on the dapagliflozin; metformin hydrochloride; saxagliptin hydrochloride profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
